Bioventus BVS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $576.3M+1.4% | $568.09M+0.8% | $563.83M-0.1% | $564.14M-0.6% | $567.7M-1.0% | ||
| $180.43M+0.3% | $179.93M-1.0% | $181.8M-0.5% | $182.79M-1.1% | $184.8M-0.1% | ||
| $395.87M+2.0% | $388.16M+1.6% | $382.03M+0.2% | $381.35M-0.4% | $382.9M-1.4% | ||
| 68.7%+0.4pp | 68.3%+0.6pp | 67.8%+0.2pp | 67.6%+0.2pp | 67.4%-0.3pp | ||
| $11.57M-4.5% | $12.11M-2.1% | $12.38M-6.9% | $13.3M-7.2% | $14.34M+2.8% | ||
| $318.85M+1.5% | $314.03M-1.3% | $318.14M-0.9% | $320.97M-5.2% | $338.53M-1.5% | ||
| $5.24M-8.5% | $5.73M-7.6% | $6.2M-9.7% | $6.87M-8.3% | $7.49M-2.1% | ||
| —— | —— | —— | —— | -$52K0.0% | ||
| $57.52M+6.6% | $53.98M— | —— | —— | —— | ||
| 10%+0.5pp | 9.5%— | —— | —— | —— | ||
| -$23.3M+12.0% | -$26.49M+12.2% | -$30.18M+10.0% | -$33.53M+6.8% | -$35.96M+7.3% | ||
| -$23.88M+15.5% | -$28.27M+7.9% | -$30.68M+7.0% | -$33M+5.8% | -$35.03M+5.7% | ||
| $0+100% | -$81K+78.3% | -$373K+0.3% | -$374K-0.3% | -$373K-27.7% | ||
| $33.64M+30.9% | $25.71M+123% | $11.51M+627% | $1.58M+103% | -$50.29M+3.9% | ||
| -$899K+42.6% | -$1.57M— | —— | —— | —— | ||
| $28.48M+25.3% | $22.73M+200% | $7.59M+1,138% | -$731K+97.8% | -$33.87M+6.2% | ||
| 4.9%+0.9pp | 4%+2.7pp | 1.3%+1.5pp | -0.1%+5.8pp | -6%+0.3pp | ||
| $0.41+24.2% | $0.33+175% | $0.12+1,300% | -$0.01+98.1% | -$0.52+7.1% | ||
| $0.43+26.5% | $0.34+183% | $0.12+1,300% | -$0.01+98.1% | -$0.52+7.1% | ||
| 276.3M+1.5% | 272.3M+1.6% | 267.9M+1.4% | 264.4M+1.7% | 259.9M+1.0% | ||
| 267.3M+0.5% | 266.1M+0.8% | 264M+0.6% | 262.3M+0.9% | 259.9M+1.0% | ||
| -$23.3M+12.0% | -$26.49M+12.2% | -$30.18M+10.0% | -$33.53M+6.8% | -$35.96M+7.3% | ||
| $28.27M+20.8% | $23.41M+341% | $5.31M+457% | -$1.49M+95.9% | -$36.26M+8.2% | ||
| $0+100% | -$81K+78.3% | -$373K+0.3% | -$374K-0.3% | -$373K-27.7% | ||
| $9K+101% | -$991K-26.2% | -$785K— | $0— | —— | ||
| -$295K-116% | $1.81M+188% | -$2.06M-115% | -$957K+67.8% | -$2.98M+29.0% | ||
| —— | -$21K-10.5% | -$19K-11.8% | -$17K-13.3% | -$15K-15.4% | ||
| -$250K+82.8% | -$1.45M-726% | -$176K-133% | $529K-43.2% | $931K-43.4% | ||
| $576.3M+1.4% | $568.09M+0.8% | $563.83M-0.1% | $564.14M-0.6% | $567.7M-1.0% | ||
| $57.52M+6.6% | $53.98M+112% | $25.44M+42.6% | $17.83M+156% | -$32.01M-0.2% | ||
| $103.87M+2.9% | $100.99M+38.0% | $73.16M+10.1% | $66.43M+277% | $17.63M+0.1% | ||
| $103.87M+2.9% | $100.99M+38.0% | $73.16M+10.1% | $66.43M+277% | $17.63M+0.1% | ||
| 18%+0.2pp | 17.8%+4.8pp | 13%+1.2pp | 11.8%+8.7pp | 3.1%0.0pp | ||
| $57.52M+6.6% | $53.98M+112% | $25.44M+42.6% | $17.83M+156% | -$32.01M-0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bioventus's revenue?
- Bioventus (BVS) generated $576.3M in revenue over the trailing twelve months, up 1.5% year over year.
- Is Bioventus profitable?
- Bioventus reported $28.5M in net income over the trailing twelve months, a 4.9% net margin.
- What are Bioventus's profit margins?
- Gross margin is 68.7% and operating margin is 10.0%, with a 4.9% net margin.
- What is Bioventus's earnings per share?
- Bioventus's diluted EPS over the trailing twelve months is $0.41.
- Where does Bioventus's income statement data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
